PDC*line Pharma Raises €20 Million in Series B Financing Round
Summary
LIÈGE, Belgium & GRENOBLE, France--(BUSINESS WIRE)--PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. “The competitive advantage of our vaccinal platform in cancer immunotherapy and the significant achievements we have made over the last three years, including the signing of an important licensing deal with LG-Chem in Asia and the start of our phase I/II trials in France and Belgium in non-small-cell lung cancer (NSCLC), have been key factors in our investors’ decisions.” The objectives of the phase I/II study (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate, PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC. In the life sciences sector, its current portfolio includes private and public companies, in both venture and growth segments, for a total fair value close to 200 million euros. Over the years, Noshaq has developed a range of financing vehicles in line with market needs and trends and with its strategy (For example: Spinventure for the spin-offs of the University of Liège, LeanSquare for the ‘new economy’ start-ups, Epimede, a private growth fund, active in Belgium and beyond). Financière belongs to the INVESTSUD Group, which is a private venture capital firm in Wallonia, Belgium, dedicated to accompanying small- and medium-sized family companies with equity or quasi-equity funds.